Skip to main content
. 2020 Sep 3;21(17):6419. doi: 10.3390/ijms21176419

Figure 3.

Figure 3

Osmotin treatment positively modulates AD through the AdipoR1/AMPK/SIRT1 pathway. (a) Obesity reduces adiponectin and AdipoR1 expressions, which negatively modulate the AMPK/SIRT1 pathway and increase the AD biomarkers. (b) Osmotin treatment increases adiponectin and AdipoR1 expressions and reduces AD biomarkers through the AMPK/SIRT1 pathway.